Automation Solutions Firm MegaRobo Bags $300M in C-Round Financing
MegaRobo, an intelligent life science enterprise, has announced its completion of C-round financing totaling $300 million. The funding was jointly led by Goldman Sachs Asset Management LP, Asia Investment Capital and GGV Capital, with continued investment from existing shareholder Sinovation Ventures. It was also followed by Singapore’s Pavilion Capital, Starr Capital, U-MEMBER, Redview Capital, Harvest Capital and Taihecap. Additionally, a leading domestic enterprise in the field of biotechnology participated in this round of financing.
The raised funds will reportedly be used to deepen the firm’s R&D investment in the field of intelligent automation in life sciences. The firm will also actively expand business and accelerate its internationalization process.
Founded in 2016, MegaRobo provides the life science industry with fully automatic solutions, ranging from simple console workflow automation to complex steps in large-scale system process applications. It also extends to the next generation of life science infrastructure and systems that promote the R&D of AI drugs.
The firm’s automation workflow integrates AI software, analytical instruments, laboratory hardware and test consumables into a single laboratory system. Compared with the traditional laboratory system, the firm can achieve higher efficiency and more stable experimental results in various life science application fields, such as antibody selection, cell line development and molecular screening, which has been introduced and put into use in many countries around the world.
SEE ALSO: Wissen Secures $10M in Pre-A+ Financing
MegaRobo focuses on building an infrastructure called “Kunpeng Laboratory.” It carries out in-depth strategic cooperation with many leading enterprises in the field of life sciences, builds infrastructure and platforms to optimize R&D efficiency, and actively explores life science research.
The past decade has witnessed an increasing volume of small and medium-sized biotechnology companies, the accelerated assistance of capital and the expanding industry scale in the Asia-Pacific region. This has also promoted the rapid increase of R&D investment in the field of life sciences. Efficiency improvement and resource optimization have become the core points to be solved in the development of the industry, and intelligent automation is an inevitable solution to this challenge.
